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Abstract
Metallo-b-lactamases (MBLs) in Enterobacteriaceae are an increas-
ing problem worldwide. This report describes the isolation of
Citrobacter freundii carrying IMP-8 MBL from three patients during
the period from March 2012 until March 2013 in Germany. The
blaIMP-8 enzyme is predominantly found in Asia, where IMP-8 has
spread to various enterobacterial species causing serious infec-
tions. To our best knowledge, this is the first report of blaIMP-8
habouring Enterobacteriaceae in Europe.
Keywords: Antimicrobial resistance, IMP, infection control,
laboratory surveillance, metallo-b-lactamases, multidrug resistance
Original Submission: 3 October 2013; Revised Submission:
22 December 2013; Accepted: 14 January 2014
Article published online: 21 March 2014
New Microbe New Infect 2014; 2: 42–45
Corresponding author: S. Peter, Institute of Medical Microbiology
and Hygiene, Elfriede-Aulhorn-Strasse 6, 72076 T€ubingen, Germany
E-mail: silke.peter@med.uni-tuebingen.de
Introduction
The emergence and spread of carbapenemase-producing
Enterobacteriaceae is an increasing problem of global dimen-
sions. Originally, metallo-b-lactamases (MBLs) were associated
with resistance in Gram-negative non-fermenters, but they
have become increasingly important regarding carbapenem
resistance in Enterobacteriaceae. MBLs confer resistance to
almost all b-lactam antibiotics and are not inactivated by
b-lactamase inhibitors, hence limiting treatment options in the
individual patient and presenting a major challenge for infection
control within the hospital setting [1].
To date, the occurrence of carbapenem-resistant Entero-
bacteriaceae in Germany is still a rare event; however,
outbreaks involving KPC and VIM-1 carrying Klebsiella pneu-
moniae isolates have been described [2,3]. In the year 2012,
VIM-1 was the most prevalent MBL detected in Enterobacte-
riaceae in Germany, followed by NDM-1 and GIM-1 [2]. IMP
type MBLs were first identified in Pseudomonas aeruginosa in
Japan [4] and have since been reported predominantly from
Asia [5]. With the exception of Italy, IMP-type enzymes have
rarely been reported from other countries in Europe [1,5,6].
Here, we report the isolation of Citrobacter freundii
harbouring MBL IMP-8 from three patients between March
2012 and March 2013. All isolates were obtained from rectal
swabs. All three patients had underlying haematological
conditions (acute myeloid leukaemia n = 2 and myelodysplas-
tic syndrome n = 1) and underwent haematopoietic stem cell
transplantation. They were screened from rectal swabs for
colonization with multidrug resistant Gram-negative bacteria
on a weekly routine schedule.
Laboratory Analysis
Identification of the isolates was performed using matrix-as-
sisted laser desorption/ionization time of flight mass spectrom-
etry (MALDI TOF-MS) (AXIMA Assurance, bioMerieux SA,
Marcy l’Etoile, France; Saramis Database Version 4.09) and the
VITEK 2 identification system (bioMerieux SA). Antimicrobial
susceptibility testing was initially performed with the VITEK 2
system (bioMerieux SA) and confirmed by Etest (bioMerieux
SA). Results were interpreted according to the European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
guidelines (http://www.eucast.org/fileadmin/src/media/PDFs/
EUCAST_files/Breakpoint_tables/Breakpoint_table_v_3.1.pdf).
The detection of extended-spectrum b-lactamase genes
blaCTX-M, blaTEM, blaSHV, [7] and carbapenemase genes blaOXA-48
[8], blaKPC [9], blaNDM [10], blaIMP and blaVIM [11]was performed
as described previously. Sequencing of the IMP genes was
performed using class 1 integron primer 3CS (5′-AAG CAG
ACT TGA CCT GA-3′) in combination with primer IMP-A, and
5CS (5′-GGCATCCAAGCAGCAAG-3′) in combination with
primer IMP-B [11]. Sequence identification was determined by
comparison with the sequences available in GenBank (http://
www.ncbi.nih.gov/BLAST) and with the reference sequences of
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the Lahey database (http://www.lahey.org/studies). Alignment
was performed using BIOEDIT version 7.1.11 (Ibis Biosciences,
Carlsbad, CA, USA). Genomic fingerprinting of the isolates was
done by the enterobacterial repetitive intergenic consensus
(ERIC) method using the ERIC2 primer as described previously
[12]. Plasmids were extracted using the Qiagen large construct
kit (Qiagen, Hilden, Germany) and digested using EcoRI and
BamHI to allow for size estimation of the plasmids. Southern
blotting was performed following a standard protocol. Briefly,
DNA was blotted onto positively charged nylon membranes
(Roche Biochemicals, Basel, Switzerland) in denaturation solu-
tion (3 M NaCl, 0.4 M NaOH) by capillary transfer. High
stringency hybridization was performed in accordance with the
instructions given by the manufacturer of the digoxigenin
labelling and detection kit (Roche Biochemicals). Digoxigenin-
labelled DNA probes were generated with a digoxigenin-
labelling PCR kit as described in the manufacturer’s instructions
(Roche Biochemicals) using the oligonucleotides IMP-A and
IMP-B.
Results
The characteristics of the isolates are summarized in Table 1.
All three isolates were resistant to piperacillin-tazobactam,
cefuroxime and cefotaxime. The MIC of meropenem was
>32 mg/L for the isolate of patients two and three, whereas
meropenem MIC for patient one was intermediate with an
MIC of 8 mg/L. All three strains were susceptible to tigecy-
cline, colistin and amikacin. Molecular detection of ESBL genes
blaCTX-M, blaTEM, blaSHV and carbapenemase genes blaOXA-48,
blaKPC, blaNDM and blaVIM was negative in all three isolates. The
IMP PCR gave a positive result and subsequent determination
of the nucleotide sequence revealed an MBL of the IMP-8 type.
The sequence was compared with the reference sequence
(GenBank accession number AF322577) [13]. The blaIMP-8
gene detected in the three isolates harboured a non-coding
point mutation at position 18 (T?C) as shown in Fig. 1.
Additionally, an IMP-8 carrying plasmid of approximately
TABLE 1. Characteristics of IMP-8 carrying Citrobacter freundii isolates from rectal swabs of three hospitalized patients in
Germany
Patient Source Isolation date
Etest results: MIC for the antimicrobial agents in mg/L and interpretationa
TZP CXM CTX CAZ FEP ATM ERT MEM TIG CIP AN COL
1 Rectal swab March 2012 128 R >256 R 16 R >256 R 16 R 2 I >32 R 8 I 0.75 S 8 R 2 S 0.75 S
2 Rectal swab June 2012 96 R >256 R 16 R >256 R 24 R 3 I >32 R >32 R 0.75 S 16 R 2 S 1 S
3 Rectal swab March 2013 >256 R >256 R 24 R >256 R 24 R 2 I >32 R >32 R 0.75 S 12 R 2 S 1 S
I, intermediate; R, resistant; S, susceptible; AN, amikacin; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; COL, colistin; CTX, cefotaxime; CXM, cefuroxime; ERT,
ertapenem; MEM, meropenem; TIG, tigecycline; TZP, piperacillin-tazobactam.
aInterpretation according to the EUCAST clinical breakpoints (http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_3.1.pdf).
FIG. 1. Sequence of the blaIMP-8 gene of three Citrobacter freundii strains isolated from hospitalized patients in Germany. Compared with the
sequence of the IMP-8 reference strain (GenBank accession number AF322577 [13]), a non-coding point mutation at position 18 was identified in the
IMP-8 from the three Citrobacter freundii strains (grey shaded).
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28 500 bp could be isolated from all C. freundii strains.
Genomic fingerprinting by the ERIC method revealed indis-
tinguishable PCR patterns in all isolates (data not shown).
Conclusion
This is the first report of IMP-8 MBL in Enterobacteriaceae in
Germany. IMP-8 is very uncommon in Europe, only once
reported from Portugal in a Pseudomonas mendocina strain [6,
14]. In contrast, IMP-8 is frequently encountered in Asia,
especially in Taiwan, where IMP-8-producing Enterobacteria-
ceae are involved in serious infections. Yan et al. reported on a
case series of 37 patients with bloodstream infections caused
by a large variety of IMP-8-producing enterobacterial species
including Escherichia coli, K. pneumoniae, Enterobacter cloacae
and C. freundii [15]. Furthermore, aggravating the issue,
phenotypic screening for IMP-8-positive Enterobacteriaceae is
extremely difficult because of the lack of distinctive pheno-
types. Investigation of 95 IMP-8-positive Enterobacteriaceae
revealed susceptibility to ertapenem in 21% and to merope-
nem in 45%, whereas phenotypic combined disk tests using
EDTA and phenylboronic acid were positive in only 40% of the
isolates [16]. These observations from Taiwan suggest that
IMP-8 is capable of spreading between enterobacterial species,
causing serious problems in terms of infection control
measures and limiting therapeutic options in critically ill
patients.
The role of faecal carriage of MBL-producing Enterobacte-
riaceae remains unclear and has not been investigated in a
large-scale epidemiological study. Faecal carriage of one
C. freundii VIM-1 has been reported from Spain in an outpa-
tient, who was also colonized with two different VIM-1-car-
rying K. pneumoniae isolates [17]. In an Italian hospital, eight
VIM-1-carrying C. freundii strains were isolated from rectal
swab samples during active screening following the detection
of a K. pneumoniae carbapenemase (KPC) -positive patient
[18].
None of our three patients became infected by the IMP-8
C. freundii strains, but nevertheless it is alarming that IMP-8
MBL circulates in the gut flora of patients at high risk of
nosocomial infections. Even more worrisome is the fact, that
the IMP-8 gene is located on a plasmid, which might facilitate
the transfer of the resistance gene within enterobacterial
species. Our findings emphasize the importance of establishing
screening schemes and laboratory diagnostic algorithms to
ensure the implementation of efficient infection control
measures and therapeutic strategies, not only in high-preva-
lence countries, but also in countries with a low incidence of
MBL producing Enterobacteriaceae.
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